Litcius/Paper detail

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron, Bruce R. Smith, Pedro Cahn, Guillermo M. Ruiz‐Palacios, Aamer Ikram, Fernando Laņas, M. Lourdes Guerrero, Sergio Raúl Muñoz Navarro, Omar Sued, Dmitry Lioznov, Vitalina Dzutseva, Ghazala Parveen, Fengcai Zhu, Laura Leppan, Joanne M. Langley, Luis Barreto, Jin-Bo Gou, Tao Zhu, Helen Mao, Luc Gagnon, Steven-Phay Tran, S. Khan, Amalia Guadalupe Becerra Aquino, Edgar Eduardo Saldaña Montemayor, Norma E. Rivera-Martínez, Víctor Casildo Bohórquez López, Jesus Abraham Simón Campos, Felipe de Jesús Pineda Cárdenas, Wei Chen, Lihua Hou, Zhe Zhang, Gonzalo Corral, Eduardo López, Ricardo Teijeiro, María Fernanda Alzogaray, Cesar Javier Zaidman, Gustavo Lopardo, Bernardo Goecke, Rosa María Feijooó Seoane, Sayed Faisal Mahmood, Ejaz Ahmed Khan, Jayed Akram, Salma Abbas, Naseem Salahuddin, E. G. Rozhkova, Tatyana Zubkova

2021The Lancet237 citationsDOIOpen Access PDF

Topics & Concepts

ImmunogenicityInterimInterim analysisVirologyMedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Recombinant DNAVector (molecular biology)2019-20 coronavirus outbreakClinical trialImmunologyInternal medicineBiologyImmune systemOutbreakGeographyBiochemistryInfectious disease (medical specialty)GeneDiseaseArchaeologyVirus-based gene therapy researchSARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial | Litcius